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Alpha-Adrenergic Blockade in Vasotonic Angina: Lack of Efficacy of
Specific Alpha1-Receptor Blockade With Prazosin
ROSE MARIE ROBERTSON , MD, FACC, YVONNE D. BERNARD. RN. R. KEITH CARR, PhD,
DAVID ROBERTSON , MD
Nashville. Tennessee
To clarify the possible role of the alphaj-adrenergic re-
ceptor in angina due to coronary artery spasm, a double-
blind, randomized, placebo-controlled trial of the spe-
cificalpha-antagonist, prazosin , was performed. Six pa-
tients with vasotonic angina were studied, with efficacy
measured by continuous electrocardiographic recording
and the tabulation of chest pain and nitroglycerin usage.
Despite plasma prazosin levels adequate to produce a
six-fold shift in the response to phenylephrine, there was
no significant difference in the number of ischemic ep-
The cause of the transient coronary occlusion responsible
for vasotonic angina remains uncertain. It has been sug-
gested that an increase in autonomic input to the coronary
arteries may lead to focal vasospasm through activation of
alpha-adrenergic receptors in the epicardial coronaryarteries
(1-4) . However, careful evaluation (5) of the sympathetic
nervous system in patients with vasotonic angina has shown
no generalized excess of adrenergic activity. and catechol-
amine levels in the coronary sinus do not increase before
episodes of coronary spasm (6). Despite this evidence against
a signifi cant role for generalized excess sympathetic activ-
ity. it is still possible that a small but highly targeted release
of norepinephrine or an abnormalcoronary vascular segment
with excess alpha-adrenergic receptor density or reactivity
could produce focal spasm. Prior studies (1-3) have sug-
gested that nonspecific alpha-receptor blockade might lessen
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isodes while taking prazosin (9.8 ± 6,3 episodes/24 h)
compared with placebo (10.5 ± 6.9). There was also no
difference in the length of ischemic episodes, which av-
eraged 231 ± 35 seconds with placebo and 231 ± 33
with prazosin. Chest pain and nitroglycerin usage were
not altered by prazosin. These data suggest that coro-
nary artery spasm is not primarily caused by an effect
on or an abnormality of the coronary vascular alphaj-
receptor.
variant angina. Although it was originally thought that these
data reflected the effect of blocking the alpha- receptor, it
has been suggested that postsynaptic alphaj-receptors may
also produce vasoconstriction, at least in some vessels (7).
We approached these issues with a double-blind, placebo-
controlled study of specific alphaI-receptor blockade with
prazosin.
Methods
Study patients. We studied six patients (three men and
three women aged 38 to 73 years. mean 56). All patients
presented with episodes of ischemic cardiac pain at rest.
and at the time of this study had had these symptoms for
longer than 2 months (range 2 to 122, mean 37). Hemo-
dynamicmonitoring demonstrated that there was no increase
in intraarterial blood pressure or heart rate before episodes
of ST elevation at rest. In four patients. coronary spasm
was visualized at angiography: it was spontaneous in two
patients and both spontaneous and exercise-induced in two.
Three patients had normal exercise tolerance without isch-
emia, two had reproducible exercise-induced coronary spasm
and one patient who had limiting arthritis did not undergo
exercise testing. The angiographic appearance of the artery
or arteries involved by spasm and other clinical data are
shown in Table I.
Trial protocol. Patients were hospitalized throughout
this trial, which consisted of a 3 day trial of prazosin and
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Table 1. Summary of Clinical Data in Six Patients
Symptom,
Durat ion
Age (y r ) of Unprovoked Exercise-Induced
Case &Sex (rno ) Pam Pam
38M 36 Yes No
2 55F 122 Yes No
3 47F 4 Ye, No
4 68M 2 Ye~ Ye,
5 73F II Yes Limited by arthnus
6 57M 4l! Ye, Ye,
Coronary
Angiography*
35'1< LAD
Normal
Normal
SO 10 70% OM
70 (0 90'* RCA
30 to 50'k OM
*Degree of arteriographic narrowing of the coronary vessel involved by spasm a, Judged after nitroglycerin. F = female: LAD = left anterior
descending artery: M = male: OM = obtuse marginal branch of circumflex artery : RCA = right coronary artery
10 0 0
300 0
000
o
0-'-----------
Prcz osmCo nt ro l
Results
Evaluation of alpha-receptor blockade (Fig. 1). In the
normal subjects. increasing doses of prazosin caused an
increase in the dose of phenylephrine needed to produce
any given increase in intraarterial pressure. A 2 mg oral
dose of prazosin (corresponding to plasma levels of 20 nglml)
caused a greater than sixfold shift in the phenylephrine dose-
response curve. In the patient group. the trough prazosin
levels on the day of maximal prazosin dosage regimen ranged
P HE25
( p g)
2000
Analysis. The average number of episodes of ST ele-
vation per day and their average length during the placebo
period were compared with the number and length during
the entire prazosin period and on the day of highest prazosin
dose. using analysis of variance and paired Student' s t tests.
Figure L Dose of intravenous phenylephrine (PHE25) required to
increase the directly measured systolic arterial pressure by 25
mm Hg in four normal subjects. Each black circle represents the
data fro m a single titration. On the left are the doses required at
baseline. labeled control. On the right are the doses required 1
hour after 2 mg of oral prazosin. This corresponds to a six-fold
shift in the dose-response curve of phenylephrine.
4000
a 3 day placebo period in random order. All patients par-
ticipated only after giving informed consent as approved by
the Vanderbilt University Committee for the Protection of
Human Subjects. Patients and their physicians and nurses
were not aware of the agent taken. To allow an adequate
dose of prazosin to be reached safely. the dose of prazosin
administered each day was increased. beginning at I mg
every 8 hours and increasing to a maximum of 4 mg every
8 hours. The prazosin dose was doubled each day unless
systolic blood pressure had decreased to 11 0 mm Hg or less.
or if a 30 mm Hg decline in systolic blood pressure was
documented. This increase was directed by one of the in-
vestigators (D.R.l. who was blinded to the patients' anginal
symptoms, but was cognizant of their blood pressure to
assure safety.
Measures of efficacy. All patients had continuous cal-
ibrated ambulatory electrocardiographic recording through-
out the trial. Tapes were analyzed for any episode of ST
elevation (no patient had ST depression) of I mm or greater
and lasting 30 seconds or longer. not accounted for by
positional change. The number and length of all episodes
were tabulated for each 24 hour period of the trial. In ad-
dition, the heart rate at the onset of each episode was re-
corded so that the mean heart rate at the onset of ischemia
during placebo administration could be compared with that
during the period of administration of the highest prazosin
dose. Patients also kept diaries of the frequency and severity
of chest pain and records were kept of nitroglycerin usage.
During placebo and prazosin periods. sphygmomanometric
blood pressure was determined in the supine position 2 hours
after dosing. Heart rate. both supine and sitting. was mea-
sured from the continuous electrocardiographic recording.
Peak and trough levels of prazosin were assessed at maximal
dosage to assure adequacy of the dosage regimen.
To allow assessment of the alpha-receptor blocking ef-
ficacy of these levels of pruzos in. we performed dose-re-
sponse curves of intraarterial blood pressure to phenyle-
phrine before and after varying doses of prazosin in four
normal subjects. A plasma level of 20 ng/ml was associated
with a greater than sixfold shift in phenylephrine sensitivity.
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from 21 to 37 nglml. The blood pressure and heart rate
response to prazosin, as well as prazosin doses on the day
of maximal therapy, are shown in detail in Table 2. There
was no significant difference in the heart rates at which
ischemic episodes began during the placebo and prazosin
periods .
Effect on vasotonic angina. Analysis of the number of
ischemic episodes during treatment with placebo and pra-
zosin showed no significant difference between these pe-
riods, whether they were considered in the aggregate or by
individual days. There were an average of 10.5 ± 6.9
episodes/24 h while patients were receiving placebo and 9.8
± 6.3/24 h while they received the maximal dose of pra-
zosin (Fig. 2). There was also no significant difference
between the length of ischemic episodes on these two reg-
imens, with the duration of ST elevation averaging 231 ±
35 seconds (range 127 to 358) with placebo and 231 ± 33
seconds (range 148 to 364) with the highest dose of prazosin
(Fig . 3). The frequency of chest pain (4 ± 2 episodes124h
with both placebo and prazosin) and the use of nitroglycerin
(7 ± 3 tablets /24h with placebo versus 8 ± 4 tablets124h
with prazosin) were not altered by prazosin in these patients.
Discussion
Role of alpha-adrenergic stimulation in coronary
spasm. The mechanisms underlying coronary artery spasm
are still uncertain. Interest has focused on the sympathetic
nervous system for a number of reasons . Animal studies
(8-10) demonstrated the presence of alpha-receptors on the
coronary arteries. In clinical studies by Yasue et al. (l,2),
it appeared that spasm could be provoked by alpha-adren-
ergic stimulation during beta-receptor blockade, whether the
former was produced directly by epinephrine or by reflex
after parasympathetic stimulation with methacholine. Stim-
ulation or blockade of the alpha-receptor has been shown
to alter coronary blood flow in a number of animal models
(11-16), and Orlick et al. (17) demonstrated that the coro-
Table 2. Hemodynamic Responses to Prazosin in Six Patients*
nary circulation in human beings also has baseline alpha-
constrictor tone.
Prior studies (3,4) of patients with variant angina dem-
onstrated a beneficial effect of alpha-receptor blockade with
intravenous phentolamine or oral phenoxybenzamine. How-
ever. the patients in the study by Levene and Freeman (3)
had exercise-induced spasm . and this group of patients may
be more likely to have an adrenergic mechanism for their
disease than the larger group of patients with variant angina.
Role of circulating catecholamines in coronary spasm.
Because of these prior studies, we considered whether the
clinical syndromes associated with coronary spasm could
be secondary to the action of norepinephrine on the alpha-
receptor. Indeed, patients with vasotonic angina. that is,
chronic episodic coronary artery spasm with little or no
exercise-induced angina. have an increase in the length ( 18)
and possibly the frequency (19) of their attacks when they
are treated with beta-receptor blocking agents such as pro-
pranolol. However. when catecholamines were sampled in
the peripheral venous and coronary sinus blood early in
episodes of vasotonic angina, they were not increased over
baseline values, nor were they even as high as those in the
same patients with as mild a stimulus as upright posture
(5.6) . Other testing of sympathetic nervous system function
in such patients has also been normal (5) .
Despite this information, a very highly targeted increase
in the amount of norepinephrine released might not be easily
measured when combined with blood from other areas of
the heart . It also seemed possible that abnormal vascular
alpha-receptors, whether alpha) or postsynaptic alpha, (7,20) ,
might predispose to coronary spasm . In addition, it seemed
possible that this mechanism might be more likely in ex-
ercise-induced coronary spasm , where circulating norepi-
nephrine levels are increased above rest levels by the ex-
ercise. In fact, Yasue et al. (21) found that patients with
exercise-induced spasm had a high incidence of exacerba-
tion of their syndrome by propranolol, with 13 of 30 patients
noticing an increase in angina on propranolol.
Supine Blood Pressure Supme Heart Rate Ischemic Heart Rate
(mm Hg) (beats/min) (beats/min)"
Prazosin
Case PLA PRA PLA PRA PLA PRA Dose (mgj]
1 158/104 138/80 80 78 82 98 12
2 1200 1100 48 62 51 58 6
3 125175 114/82 48 52 50 62 12
4 130/66 84148 61 67 65 12
5 160/90 130/90 65 72 74 75 6
6 140/98 150/88 73 90 71 87 12
"Blood pressure and heart rate were measured 2 hours after a dose of prazosin on the day of maximal prazosin dose and at a similar time on a day
when the patient was receiving placebo t Measured at the onset of ST elevation. :j:Maximal dose received in a 24 hour period.
D = pressure obtainable only by Doppler technique in this patient with atherosclerotic narrowing of both subclavian arteries; PLA = placebo; PRA
= prazosin.
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Figure3. Comparison of themean length (in seconds)of episodes
of ST segment elevation as tabulated from continuous electrocar-
diographic recordings. Each black circle represents thedata from
one patient and the lines connect each patient's data. Prazosin
produced no alteration in the lengthof ischemic episodes. Abbre-
viations as in Figure 2.
NS,
400 NS~
MEAN
-------------LENGTHOF 300 ~ISCHEMICEPI SODES
(sec) 200 7'"~
100
Figure 2. Comparison of the mean number of episodes of ST
segment elevation per 24 hours as tabulated from the continuous
electrocardiographic recordings of the six patients during the pla-
cebo period (PLA), during the entire period of prazosin therapy
(PRA)andduring thedayofmaximal prazosin therapy (PRA max).
Each black circle represents data from a patient and the lines
connect each patient's data . There was no signifi cant difference
between theplaceboand prazosinperiods. N.S. = not significant.
References
I. Yasue H. Touyama M. Shimamoto M. Kato H. Tanaka S, Akiyama
F. Role of autonomic nervous system In the pathogenesis of Prinz-
metal's vanant form of angina. Circulanon 1974:50'534-9.
2. Yasue H, Touyama M. Kato H. Tanaka S. Akiyama F Prinzmetal' s
variant form of anginaas a manifestation of alpha-adrenergic receptor-
mediated coronary artery spasm: docurnentanon by coronary arten-
ography Am Heart J 1976;91.148-55
3. Levene DL, Freeman MR. Alpha-adrenoceptor-mediated coronary ar-
tery spasm. JAMA 1976;236:101 8-22.
4. Ricci DR. Orlick AE. CIpriano PRoGuthner OF. Hamson DC. Altered
adrenergic activity in coronary artena l spasm' insight into mechanism
based on study of coronary hemodynamics and the electrocardiogram.
Am J Cardiol 1979;43'1073- 9.
5. Robertson D. Robertson RM. Nies AS. Oates JA. Friesmger GC.
Vanant angina pectons investigation of mdices of sympathetic ner-
vous system function. Am J Cardiol 1979.43'1080-5 .
6. Robertson RM. Bernard Y. Robertson 0 Coronary sinus and arterial
catecholanunesdunng coronaryarteryspasm. AmHeartJ 1983;105:901 -
6.
7 Bassenge E. Holtz 1, Sommer O. Saeed M Vascular alpha-2-adre-
noceptors mediate coronary constncnons Induced by norepmephnne
(NEl and by sympathetic nerve stimulanon (abstr) C rrculatton
1982:66(suppl 11) '11-153.
8 McRaven DR, Mark AL. Abboud FM. ct al Responses of coronary
vessels to adrenergic stimuli J Chn Invest 1971 :50:773-8 .
9 PIll B. Elliot EC. Gregg DE. Adrenergic receptor actrvity In the
coronary artenes of the unanesthetized dog. Circ Res 1967;21.75-84
because all had angina after recent myocardial infarction
and there was severe coronary atherosclerosis in the one
patient in whom angiographic findings were reported in
detail. In addition, the response to prazosin was only partial
in two patients, and in one of these patients, spontaneous
spasm was seen at angiography while prazosin therapy con-
tinued. In several patients, the decrease in episodes of chest
pain was gradual or associated with other alterations in drug
therapy, such as a reduction in propranolol. or both. The
cyclic nature of variant angina (27,28) makes crossover or
placebo-controlled trials important in such circumstances,
and it would be useful to reexamine such a group with this
approach.
Our data demonstrate no improvement in vasotonic an-
gina despite a high level of alpha- receptor blockade. Be-
cause two of our patients had well defined exercise-induced
coronary spasm, these results appear to relate to that portion
of the spectrum of variant angina as well. Worsening of
classic angina pectoris has also been documented with pra-
zosin (29). Althoughpostsynaptic alphayreceptors might be
responsible for vasospasm, preliminary data by Chierchia
et al. (30) demonstrating no beneficial effect of phentolam-
ine on angina in patients with coronary spasm make this
seem unlikely. Thus, although alterations in autonomic tone
may exacerbate or lessen coronary artery spasm in some
situations, the specific group of patients in our study appear
to have another, as yet unrecognized. mechanism for spo-
radic vasoconstriction.
PRA r-ox
PRAmo,
PRA
PRA
PLA
PLA
5 0
40
3 0
20
24 HRS 4
3
2
1
Effect of selective alpha.-blockade with prazosin on
vasotonic angina. Because of the suggestion of effective-
ness of nonspecific alpha-receptor blockade with phento-
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receptor blockade would offer the most information regard-
ing mechanisms in this syndrome. Phentolamine, like phen-
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is a selective alpha-receptor blocking agent (23-25) .
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